The international market access checklist for MedTech startups in 2027 is a sequenced set of regulatory checkpoints, one per target jurisdiction: the EU under Regulation (EU) 2017/745 (MDR), the US under the FDA device framework, the UK under the MHRA and UKCA route, Canada under Health Canada with MDSAP as the mandatory QMS spine, Australia under the TGA, Japan under the MHLW and PMDA, and Brazil under ANVISA. Each jurisdiction has its own classification logic, its own QMS expectations, its own clinical evidence standard, and its own cost and timeline profile. A CE certificate does not give access to any of the others. A startup that wants multi-market access plans the sequence, the QMS overlay, the local representation, and the translation requirements up front — not after CE marking is finished.

By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.

TL;DR

  • Market access is national or regional. There is no global medical device certification, and no mark or clearance in one jurisdiction automatically gives access to another.
  • The EU MDR, Regulation (EU) 2017/745, is the regulatory spine for European market access. For most devices above Class I, a Notified Body conformity assessment under MDR Article 52 leads to a CE certificate and the manufacturer's Declaration of Conformity under Article 20.
  • The US, UK, Canada, Australia, Japan, and Brazil each run their own framework with their own premarket submission and their own QMS inspection regime. MDSAP covers the QMS inspection layer for five of them (US, Canada, Australia, Japan, Brazil); it does not cover the EU or the UK and it does not replace any premarket submission.
  • A single well-built QMS grounded in EN ISO 13485:2016+A11:2021 is the reusable asset across every jurisdiction. Everything else — clinical strategy, labelling, local representation, translation — has to be planned jurisdiction by jurisdiction.
  • The honest sequence for a resource-constrained startup is one lead market first, deep and clean, then adjacent markets added in a deliberate order driven by the business plan, not by investor slide aesthetics.

Why this checklist exists — the German company that assumed CE was global

A German MedTech company Tibor worked with had built a clever Class IIa device, earned a CE mark under the MDR, and walked into an investor meeting with a business plan that showed parallel launches in the US, Brazil, Japan, and Australia within 18 months. The pitch was compelling: "We have CE, the hardest regulatory hurdle in the world. Everything else is adaptation."

When the investor asked how the CE certificate helped in the United States, the founder said CE was "international." The meeting ended without a term sheet. The company spent the next months rebuilding the international plan from scratch. New classification analysis for each jurisdiction. New QMS gap analysis. New clinical evidence review. New local representative contracts. New translation and labelling work. Timelines pushed back by years, not months. Additional costs in the six figures per market that had never been in the budget.

The CE work was not wasted. It was just not a US submission, not an ANVISA registration, not a PMDA marketing authorisation, and not a TGA inclusion. CE marking is valid in the European Economic Area. That is 30 countries. Not the world.

This is the single most common dual-market mistake Tibor sees. The checklist below exists so the next founder does not make it.

A note on scope: Tibor's regulatory authority is the EU MDR and the Notified Body system. For non-EU jurisdictions, this post frames each system at the general level — enough to plan and sequence, not enough to draft a submission. Jurisdiction-specific drafting belongs to a local regulatory specialist practising inside that system daily.

H2: The EU — MDR as the baseline

The European Union regulates medical devices under Regulation (EU) 2017/745 (MDR). For most devices above Class I, placing the device on the EU market requires a Notified Body conformity assessment under MDR Article 52 — typically the Annex IX route of QMS plus technical documentation assessment — leading to a CE certificate and the manufacturer's EU Declaration of Conformity under Article 20. The underlying QMS obligation in MDR Article 10(9) is supported by EN ISO 13485:2016+A11:2021 as the harmonised standard.

EU checklist:

  1. Classification under MDR Annex VIII (22 rules) confirmed and justified in writing.
  2. QMS conforming to EN ISO 13485:2016+A11:2021 operational and audit-ready.
  3. Technical documentation compiled per MDR Annex II and Annex III.
  4. Clinical evaluation per MDR Article 61 and Annex XIV.
  5. Notified Body contract signed for the relevant conformity assessment route.
  6. EU Authorised Representative appointed if the manufacturer is based outside the EU/EEA.
  7. EUDAMED registration and UDI assignment.
  8. Labelling and IFU in the languages required by each Member State of sale.

The EU is the regulatory baseline for this post because it is the most documentation-heavy of the systems covered and produces the most reusable QMS and technical documentation spine for downstream jurisdictions.

H2: The United States — the FDA pathway question

The United States regulates medical devices through the FDA. Access depends on the device's classification under the FDA system and on the premarket pathway that classification triggers — most commonly the 510(k) premarket notification pathway based on substantial equivalence to a predicate, the De Novo pathway for novel low-to-moderate risk devices without a predicate, and the PMA pathway for most Class III devices. The QMS inspection layer is governed by the FDA's quality system requirements, which the agency is bringing into closer alignment with ISO 13485 through the QMSR initiative.

US checklist:

  1. FDA classification confirmed by product code and regulation number (not by MDR class).
  2. Premarket pathway selected (510(k), De Novo, or PMA) with rationale.
  3. Predicate analysis completed for 510(k) pathways.
  4. QMS gap analysis against US quality system expectations.
  5. US Agent appointed for non-US manufacturers.
  6. Establishment registration and device listing prepared.
  7. Labelling reviewed against FDA labelling expectations.
  8. MDSAP considered as an efficiency layer for the QMS inspection burden.

A CE certificate does not translate into a US classification. A device that is Class IIa under the MDR can legitimately land in a different FDA class because the two systems use different logic. Planning this at the start of development — not after CE marking — is the difference between a clean dual-market launch and the German company's story above.

H2: The United Kingdom — MHRA and the UKCA route

Since Brexit, the United Kingdom regulates medical devices separately from the EU, through the Medicines and Healthcare products Regulatory Agency (MHRA). The UKCA marking route applies to Great Britain (England, Scotland, and Wales), and the UK system has its own transitional arrangements and its own framework reforms in progress. Northern Ireland has its own arrangements under the Windsor Framework.

UK checklist:

  1. Current UK regime status confirmed with the MHRA for the relevant device class and target date — this is a moving target and must be checked in writing before planning.
  2. UK Approved Body contract where third-party assessment is required.
  3. UK Responsible Person appointed for non-UK manufacturers.
  4. MHRA device registration.
  5. Labelling reviewed against the UK requirements in force at the time of placing on the market.

The UK is a small enough market that many startups defer it past the EU launch. It is also a regulatory regime in flux, and the sensible posture for a startup is not to guess at future rules but to make a call once the launch window is inside twelve months and the current rules are knowable with certainty.

H2: Canada — Health Canada with MDSAP as the mandatory spine

Canada regulates medical devices through Health Canada, which issues Medical Device Licences for Class II, III, and IV devices under the Canadian classification. MDSAP is effectively mandatory for those classes: a manufacturer without a valid MDSAP certificate from a recognised Auditing Organisation cannot hold a Canadian Medical Device Licence for those classes. This is the sharpest single driver in the MDSAP program and the reason Canada is usually the decision pivot for a startup's multi-market QMS strategy.

Canada checklist:

  1. Canadian classification confirmed (note: Canada uses Class I–IV, which does not map 1:1 to MDR or FDA classifications).
  2. MDSAP engagement scoped and an MDSAP-recognised Auditing Organisation contracted.
  3. QMS grounded in EN ISO 13485:2016+A11:2021 with the Canadian regulatory overlay.
  4. Medical Device Licence application prepared.
  5. Canadian Medical Device Establishment Licence where applicable to the business model.

If Canada is in the three-year plan, MDSAP scoping should start at QMS design. Retrofitting MDSAP overlays into a QMS that was built for EU purposes only is harder than building them in from the start.

H2: Australia — the TGA and the MDSAP bridge

Australia regulates medical devices through the Therapeutic Goods Administration (TGA) under the Therapeutic Goods Act and the Medical Devices Regulations. Market access requires inclusion of the device on the Australian Register of Therapeutic Goods (ARTG) by a sponsor. The TGA accepts MDSAP audit reports as one of several evidence routes for the QMS-related conformity requirements under conditions set out in TGA guidance.

Australia checklist:

  1. Australian classification confirmed under the TGA system.
  2. Conformity assessment evidence route chosen (including whether MDSAP is used as the QMS evidence).
  3. Australian Sponsor appointed (an Australian legal entity is required).
  4. ARTG inclusion application prepared.
  5. Labelling reviewed against Australian requirements.

Australia is often the cleanest second market after the EU for startups whose business plan actually has Australian customers in it. The TGA framework has historical links to the European model that reduce the mental overhead of the transition compared to jumping straight into the US system.

H2: Japan — PMDA and the MHLW framework

Japan regulates medical devices under the Pharmaceuticals and Medical Devices Act (PMD Act), administered by the Ministry of Health, Labour and Welfare (MHLW) with the Pharmaceuticals and Medical Devices Agency (PMDA) as the review body. The Japanese system has its own classification structure, its own marketing authorisation pathways, and its own QMS ordinance that governs QMS conformity assessment. Japan participates in MDSAP, and MDSAP audit reports inform the QMS conformity assessment for devices in scope.

Japan checklist:

  1. Japanese classification confirmed under the PMD Act framework.
  2. Marketing Authorisation Holder (MAH) or Designated MAH arrangement in place — a Japanese legal entity is required for the role.
  3. Pathway selected (notification, certification, or approval depending on class and novelty).
  4. QMS conformity assessment evidence prepared, including MDSAP where used.
  5. Japanese-language labelling and IFU prepared.

Japan is a high-value market and a high-effort market. Startups that do well in Japan usually go in with a committed local partner who knows the PMDA framework from the inside. Startups that assume English-language documentation and a CE mark will carry them are the ones who stall.

H2: Brazil — ANVISA and MDSAP as the GMP bridge

Brazil regulates medical devices through the Agência Nacional de Vigilância Sanitária (ANVISA). Market access requires registration of the device with ANVISA, with requirements that scale with the risk class under the Brazilian framework. The Good Manufacturing Practices (GMP) assessment, which has historically required direct ANVISA inspection, is where MDSAP provides the cleanest bridge: ANVISA uses MDSAP audit reports as part of its GMP assessment process for in-scope devices.

Brazil checklist:

  1. Brazilian classification confirmed under the ANVISA framework.
  2. Brazilian Registration Holder (a Brazilian legal entity) appointed.
  3. Registration pathway selected based on risk class.
  4. GMP evidence prepared, using MDSAP where applicable.
  5. Portuguese-language labelling and IFU prepared.

Brazil historically had a reputation for long timelines on direct GMP inspections. The MDSAP route is the material improvement, and it is why manufacturers with Brazil in the plan routinely include ANVISA in their MDSAP scope.

H2: The sequencing strategy — one market, then the next

The honest sequence for a resource-constrained startup is not "all seven jurisdictions in eighteen months." The sequence that works is:

  1. Lead market first. Pick the one market where the revenue assumption is real and the regulatory effort is known. For most European startups, this is the EU under the MDR. For some startups with a US-native customer base, it is the United States. For very few startups, it is somewhere else — and those startups usually know why.
  2. Build the spine in the lead market. A real QMS, real technical documentation, real clinical evidence. Clean enough that the downstream jurisdictions can extend from it instead of starting over.
  3. Add the second market once the first is stable. Not during. After. The calendar cost of running a first CE submission and a first 510(k) in parallel is usually larger than the calendar cost of sequencing them, because every mistake in the first submission compounds in the second.
  4. Plan MDSAP at QMS design time if Canada, Brazil, or multiple MDSAP jurisdictions are in the three-year plan. Retrofitting is harder than building in.
  5. Add the UK, Japan, Australia, and Brazil in the order the business plan actually justifies — not in the order that looks balanced on an investor slide.

The subtraction move is ruthless: cut the jurisdictions that are in the plan because they "sound global" rather than because a customer in that jurisdiction is ready to buy. Every jurisdiction you carry costs real money in local representation, translation, labelling maintenance, and surveillance obligations for years. A market you are not serving is a liability, not an asset.

H2: Translation and local representation — the hidden baseline

Every jurisdiction in this checklist requires at least one of: a local legal entity, a designated representative, a sponsor, a registration holder, an authorised representative, a UK responsible person, a US agent, a Marketing Authorisation Holder, or a Brazilian Registration Holder. The roles have different names and different legal weights, but the pattern is identical — if you are not locally established, someone local has to hold the legal accountability.

Translation requirements follow a similar pattern. The EU requires labelling and IFU in the languages of each Member State of sale. The UK requires English. The US requires English. Canada requires English and French. Japan requires Japanese. Brazil requires Portuguese. Australia requires English. Each translation must be controlled, version-managed, and maintained under the QMS — not treated as a one-time vendor task.

Translation and representation checklist:

  1. Local representation identified for every jurisdiction in scope, with a signed contract, not a handshake.
  2. Language plan mapped per jurisdiction with version control through the QMS.
  3. Labelling review process defined per jurisdiction, with named owners.
  4. Ongoing obligations of the local representative documented (vigilance reporting, regulatory correspondence, audit support).

The cost of getting this wrong is not just financial. Some jurisdictions will not accept a submission without the local role in place. Some will deregister a product if the local role lapses without replacement. The representative relationship is a live regulatory asset, not a signed document in a folder.

H2: Cost and timeline planning

The honest answer on cost is that every jurisdiction adds real cost in four layers: premarket work (classification, documentation, clinical evidence for the jurisdiction's framework), local representation (legal entity fees, ongoing retainers), QMS overlay (MDSAP costs where applicable, country-specific procedures), and surveillance and maintenance (post-market obligations, labelling updates, vigilance reporting). None of these layers is one-time.

We are deliberately not publishing specific euro or dollar figures per jurisdiction in this post. The numbers move with Notified Body availability, Auditing Organisation schedules, local representative rates, exchange rates, and program updates. The honest work is getting written quotes from the bodies involved for your specific scope, not reading a blog post's cost table from 2023. What we will commit to is the pattern: every jurisdiction beyond the lead market adds six figures of setup cost over the first two years and a meaningful ongoing annual maintenance cost thereafter.

Timelines follow the same pattern. A lead market launch that runs clean is faster than two parallel launches that stall each other. A sequenced rollout is usually twelve to twenty-four months slower on paper than a parallel rollout — and almost always faster in reality, because the parallel rollout's hidden failure modes compound.

The Subtract to Ship angle — global is a decision, not a default

The Subtract to Ship framework applied to international expansion is the same framework applied to any regulatory work: cut everything that does not trace to a specific regulatory obligation in a specific market you are actually serving. The twist is that "actually serving" is the load-bearing phrase.

The pattern that burns out startups is treating global access as the default and letting the business plan drift into seven jurisdictions because it looks ambitious. The pattern that ships is treating each jurisdiction as a deliberate decision with a named customer, a named local representative, a named regulatory lead, and a budget line that survives an investor's stress test.

Subtraction in international market access means cutting the jurisdictions you do not have a plan for, cutting the labelling languages you do not sell into, cutting the MDSAP scope that covers markets you will not enter in three years, and cutting the parallel work streams that pretend to be efficient but are actually stalling each other. What is left is a smaller, honest multi-market plan that you can execute. Every jurisdiction in it is there because a customer is there. None of it is there for the slide.

Reality Check — Where do you stand on international market access?

  1. Which specific jurisdictions are in your three-year plan, with a target launch date, a customer assumption, and a revenue line? Anything else is a preference, not a plan.
  2. Do you understand that a CE certificate gives you the European Economic Area and nothing else?
  3. For each non-EU jurisdiction in your plan, have you identified the local representative or legal entity role and confirmed it is available to you?
  4. Is MDSAP in your QMS plan if Canada is in your market plan — not as a later add, but from QMS design?
  5. Have you separated lead-market execution from second-market planning so the second market is not stealing calendar time from the first?
  6. Do your investor materials describe the international sequence honestly, or do they imply simultaneous global launch that your plan cannot actually deliver?
  7. If you had to pick one market to drop from your plan today to save twelve months, which one, and why — and if you cannot answer that question, is the plan a plan yet?

If more than three of these produced a "not yet," your international plan is the German company's plan. Fix it now, not after the investor meeting.

Frequently Asked Questions

Is there a single international certification that covers all MedTech markets? No. There is no global medical device certification. Market access is granted jurisdiction by jurisdiction. The closest thing to cross-border efficiency is MDSAP, which addresses the QMS inspection layer for five jurisdictions (US, Canada, Australia, Japan, Brazil) but does not cover the EU or the UK and does not replace any premarket submission.

Does a CE certificate under the MDR give me access to the US, UK, or Canada? No. A CE certificate applies only in the European Economic Area. The US, UK, Canada, and every other non-EEA jurisdiction each run their own framework with their own premarket submission and their own QMS expectations. A CE certificate is a valuable regulatory asset for EU access and a useful signal to some international reviewers, but it does not grant access to any jurisdiction outside the EEA.

Which market should a European MedTech startup enter first after the EU? It depends on the business plan. The most common honest second markets are the US for startups with a real US customer base, Canada for startups whose clinical customer base is North American, and the UK or Australia for startups with existing commercial relationships there. The wrong answer is "all of them at once." The right answer is the one with a named customer ready to buy at a reasonable cost of entry.

Is MDSAP required for international market access? Not universally. MDSAP is effectively required for Canada at Class II and above under the Canadian classification. For the other four participating authorities (US, Australia, Japan, Brazil) it is a recognised route but not the only route. For the EU and the UK, MDSAP does not apply — they run their own conformity assessment frameworks.

Do I need a separate QMS for each jurisdiction? No, and building parallel QMSs per jurisdiction is one of the most expensive mistakes a multi-market startup can make. The pattern that works is one real QMS grounded in EN ISO 13485:2016+A11:2021, with country-specific overlays for each jurisdiction's regulatory specifics. That is the model MDSAP audits, and it is the model that extends cleanly from the EU baseline into each additional market.

How early in development should I plan international market access? As early as the business plan identifies more than one target jurisdiction. Classification differences, clinical evidence expectations, QMS overlays, and local representation decisions are all easier to build in from the start than to retrofit after CE marking. The German company in the opener retrofitted, and it cost them an investor relationship, a year of runway, and a full business plan rewrite.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (MDR), Articles 10, 20, 52, and Annex IX. Official Journal L 117, 5.5.2017. The EU regulatory spine for this checklist.
  2. EN ISO 13485:2016 + A11:2021 — Medical devices — Quality management systems — Requirements for regulatory purposes. The harmonised QMS standard referenced by the MDR and the reusable spine across jurisdictions.
  3. Medical Device Single Audit Program (MDSAP) — program documentation maintained by the International Medical Device Regulators Forum (IMDRF) and the participating regulatory authorities (US FDA, Health Canada, TGA, MHLW/PMDA, ANVISA). Referenced at the general framing level; for current program parameters, consult a recognised Auditing Organisation.
  4. US Food and Drug Administration, UK Medicines and Healthcare products Regulatory Agency (MHRA), Health Canada, Australia Therapeutic Goods Administration (TGA), Japan Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA), and Brazil Agência Nacional de Vigilância Sanitária (ANVISA) — the non-EU regulatory authorities referenced in this post at the general framing level.

This post is part of the FDA & International Market Access series in the Subtract to Ship: MDR blog. Authored by Tibor Zechmeister and Felix Lenhard. Global access is not a default and it is not a slide. It is a sequence of deliberate decisions, each attached to a real customer in a real market. Make the sequence honest, cut the jurisdictions you are not serving, and the plan starts to hold weight.